Charles River Laboratories International (CRL) Cash & Equivalents (2009 - 2025)

Charles River Laboratories International's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $213.8 million for Q4 2025.

• In Q4 2025, Cash & Equivalents rose 9.85% year-over-year to $213.8 million; the TTM figure through Dec 2025 stood at $213.8 million (up 9.85% YoY), while the FY2025 annual figure was $213.8 million, up 9.85% from the prior year.
• Cash & Equivalents was $213.8 million for Q4 2025 at Charles River Laboratories International, up from $207.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $465.4 million in Q1 2021 to a low of $157.2 million in Q3 2023.
• Historically, Cash & Equivalents has averaged $229.6 million across 5 years, with a median of $211.4 million in 2021.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents tumbled 48.03% in 2022, then jumped 62.23% in 2024.
• A 5-year view of Cash & Equivalents shows it stood at $241.2 million in 2021, then decreased by 3.03% to $233.9 million in 2022, then gained by 18.32% to $276.8 million in 2023, then slipped by 29.69% to $194.6 million in 2024, then gained by 9.85% to $213.8 million in 2025.
• The last three Cash & Equivalents figures came in at $213.8 million (Q4 2025), $207.1 million (Q3 2025), and $182.8 million (Q2 2025), per Business Quant data.